Matsuda Masaru's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Jun 2, 2023
- Accession no.
- 0001787306-23-000066
- Filed
- Jun 2, 2023
- Trade date
- May 27-31, 2023
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $14.3K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Matsuda MasaruCIK 0001798679 | Officer (See Remark) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 27, 2023 | Common Stock | AGrant or awardAcquired | +4,875 | $0.00 | $0 | 43,976 | Direct | |
| May 31, 2023 | Common Stock | SSaleDisposed | −1,830 | $7.80F3 | −$14,274 | 42,146 | Direct | |
| May 31, 2023 | Common Stock | AGrant or awardAcquired | +1,463 | $6.38 | +$9,333.94 | 43,609 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The transaction was executed in multiple trades in prices ranging from $7.79 to $7.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Reporting Person's title: Senior Vice President and General Counsel